21 204

Cited 129 times in

Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease

Authors
 G Hatemi  ;  A Silman  ;  D Bang  ;  B Bodaghi  ;  A M Chamberlain  ;  A Gul  ;  M H Houman  ;  I Ko¨tter  ;  I Olivieri  ;  C Salvarani  ;  P P Sfikakis  ;  A Siva  ;  M R Stanford  ;  N Stu¨biger  ;  S Yurdakul  ;  H Yazici 
Citation
 Annals of the Rheumatic Diseases, Vol.68(10) : 1528-1534, 2009 
Journal Title
 Annals of the Rheumatic Diseases 
ISSN
 0003-4967 
Issue Date
2009
MeSH
Antirheumatic Agents/therapeutic use* ; Behcet Syndrome/drug therapy* ; Evidence-Based Medicine/methods ; Humans ; Immunosuppressive Agents/therapeutic use* ; Randomized Controlled Trials as Topic ; Research Design ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Abstract
OBJECTIVES: To present and analyse the literature sources regarding the management of Behçet disease (BD) identified during the systematic literature research, which formed the basis for the European League Against Rheumatism (EULAR) evidence-based recommendations for the management of BD. METHODS: Problem areas and related keywords regarding the management of BD were determined by the multidisciplinary expert committee commissioned by EULAR for developing the recommendations. A systematic literature research was performed using MedLine and Cochrane Library resources through to December 2006. Meta-analyses, systematic reviews, randomised controlled trials (RCTs), open studies, observational studies, case control studies and case series' involving > or = 5 patients were included. For each intervention the effect size and number needed to treat were calculated for efficacy. Odds ratios and numbers needed to harm were calculated for safety issues of different treatment modalities where possible. RESULTS: The literature research yielded 137 articles that met the inclusion criteria; 20 of these were RCTs. There was good evidence supporting the use of azathioprine and cyclosporin A in eye involvement and interferon (IFN)alpha in mucocutaneous involvement. There were no RCTs with IFNalpha or tumour necrosis factor (TNF)alpha antagonists in eye involvement. Similarly controlled data for the management of vascular, gastrointestinal and neurological involvement is lacking. CONCLUSION: Properly designed, controlled studies (new and confirmatory) are still needed to guide us in managing BD.
Full Text
http://ard.bmj.com/content/68/10/1528.long
DOI
10.1136/ard.2008.087957
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Bang, Dong Sik(방동식)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/105913
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse